The Pratilas Laboratory

Pratilas Lab group photo 2022

Our lab focuses on the application of small molecule therapeutics to solid tumors harboring oncogenic activation of RAS and RAS effector pathways. We emphasize interrogation of adaptive signaling responses to small molecule inhibition of the ERK signaling pathway, to identify factors that predict and condition response to targeted therapeutics and to design novel treatment strategies.